Imagenetix has been issued a new U.S. patent (#7,612,111), which provides intellectual property protection for its 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. According to the company, in studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group, the company said.
"The issuance is a significant development relating to our novel technology in the therapeutic treatment of periodontal disease and other inflammatory related conditions,” said William P. Spencer, president of Imagenetix, in a press release. “Imagenetix now owns a broader range of intellectual property protection on our novel technology with the issuance of this U.S. patent."
